After years in a trough, dealmaking involving contract development and manufacturing organizations (CDMOs) for the biopharma and medical-device industry is poised for a revival. Pent-up private equity exits, improving credit markets, intensifying onshoring, and a shift toward more specialized, higher-value modalities are all aligning, dealmakers said. “We’ve entered 2026 with twice the value and volume of activity that we entered 2025 with – and 2025 was a growth year,” said Jeremy Johnson, senior managing director at Bourne Partners. Several catalysts for a rebound are at play, according to Johnson. Debt markets have loosened, rates are drifting down, and yields are tightening, reviving LBO financing.
Read the full article: Healthcare CDMO Deals Set for 2026 Rebound as Exits and Specialization Accelerate //
Source: https://ionanalytics.com/insights/mergermarket/healthcare-cdmo-deals-set-for-2026-rebound-as-exits-and-specialization-accelerate-dealspeak-north-america/